- Home
- NUWE vs OGEN Comparison
NUWE vs OGEN Comparison
Compare NUWE & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- OGEN
- Stock Information
- Founded
- NUWE 1999
- OGEN 1996
- Country
- NUWE United States
- OGEN United States
- Employees
- NUWE N/A
- OGEN N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- OGEN Health Care
- Exchange
- NUWE Nasdaq
- OGEN Nasdaq
- Market Cap
- NUWE 5.1M
- OGEN 5.5M
- IPO Year
- NUWE N/A
- OGEN N/A
- Fundamental
- Price
- NUWE $1.21
- OGEN $0.28
- Analyst Decision
- NUWE Strong Buy
- OGEN
- Analyst Count
- NUWE 1
- OGEN 0
- Target Price
- NUWE $17.00
- OGEN N/A
- AVG Volume (30 Days)
- NUWE 316.1K
- OGEN 1.7M
- Earning Date
- NUWE 03-04-2025
- OGEN 11-13-2024
- Dividend Yield
- NUWE N/A
- OGEN N/A
- EPS Growth
- NUWE N/A
- OGEN N/A
- EPS
- NUWE N/A
- OGEN N/A
- Revenue
- NUWE $8,969,000.00
- OGEN N/A
- Revenue This Year
- NUWE $2.18
- OGEN N/A
- Revenue Next Year
- NUWE $25.75
- OGEN N/A
- P/E Ratio
- NUWE N/A
- OGEN N/A
- Revenue Growth
- NUWE 3.66
- OGEN N/A
- 52 Week Low
- NUWE $0.92
- OGEN $0.25
- 52 Week High
- NUWE $27.65
- OGEN $6.22
- Technical
- Relative Strength Index (RSI)
- NUWE 53.66
- OGEN 38.94
- Support Level
- NUWE $0.99
- OGEN $0.34
- Resistance Level
- NUWE $1.26
- OGEN $0.42
- Average True Range (ATR)
- NUWE 0.08
- OGEN 0.05
- MACD
- NUWE 0.02
- OGEN -0.01
- Stochastic Oscillator
- NUWE 81.48
- OGEN 5.05
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.